UT Health San Antonio Multispecialty and Research Hospital has enrolled and treated its first clinical trial participant in a novel cancer study, marking a pivotal moment for science and patient-centered cancer care in San Antonio and South Texas.

A drug once known almost exclusively for preventing organ transplant rejection is now at the center of a National Institute on Aging-funded clinical study at UT Health San Antonio, to determine how rapamycin should be used in older adults to promote healthy aging.

In its first appearance in the national standings as a united institution, UT San Antonio posted a strong performance in the latest rankings from the Blue Ridge Institute for Medical Research. The Blue Ridge Institute is an independent nonprofit organization that compiles annual funding data from the National Institutes of Health.

The Sam and Ann Barshop Institute for Longevity and Aging Studies at UT Health San Antonio, will receive up to $38 million to lead a national clinical trial funded by the Advanced Research Projects Agency for Health (ARPA-H), an agency of the U.S. Department of Health and Human Services.

A five-year, $9 million National Institutes of Health National Institute of Neurological Disorders and Stroke study that began in 2022 recently received approval at the three-year mark, allowing investigators to continue their work examining the biological mechanisms of TMJ disorders.